NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
Novartis
AstraZeneca
Minghui Pharmaceutical (Hangzhou) Ltd
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Novartis
CSPC Ouyi Pharmaceutical Co., Ltd.
EQRx International, Inc.
Novartis
Sanofi
AstraZeneca
Bristol-Myers Squibb
Academy Military Medical Science, China